General
Preferred name
OMIPALISIB
Synonyms
GSK2126458 ()
GSK2126458A ()
GSK458 ()
GSK 2126458 ()
Omipalisib (GSK2126458) ()
GSK-2126458 ()
P&D ID
PD010901
CAS
1086062-66-9
Tags
available
drug candidate
Drug indication
Lymphoma
Neoplasm
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Omipalisib (GSK2126458) is a potent dual inhibitor of phosphoinositide 3-kinase α (PI3Kα) and the mammalian target of rapamycin (mTOR). It is compound 1 in .
DESCRIPTION
Omipalisib (GSK2126458) is a potent dual inhibitor of phosphoinositide 3-kinase α (PI3Kα) and the mammalian target of rapamycin (mTOR). It is compound 1 in . It was originally developed for anti-proliferative activity in cancer, but has been repositioned as a potential idiopathic pulmonary fibrosis (IPF) therapy .
(GtoPdb)
DESCRIPTION
Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110¦Á/¦Â/¦Ä/¦Ã, mTORC1/2, respectively. Omipalisib has anti-cancer activity[1][2][3].
PRICE
97
DESCRIPTION
Highly potent pan-Src/Bcr-Abl inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Omipalisib, also known as GSK2126458, is asmall-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. PI3K inhibitor GSK2126458 binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Omipalisib (GSK2126458) is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
11
Organisms
2
Compound Sets
22
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LINCS compound set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
26
Molecular Weight
505.1
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
5
Aromatic Ring Count
5
cLogP
4.84
TPSA
106.96
Fraction CSP3
0.04
Chiral centers
0.0
Largest ring
6.0
QED
0.35
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
PIK3CA,PIK3CB,PIK3CD,PIK3CG
Pathway
Autophagy
PI3K/Akt/mTOR signaling
PI3K/Akt/mTOR
Primary Target
PI 3-kinase
MOA
Inhibitor
mTOR inhibitor, PI3K inhibitor
Target
MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG
PI3K/mTOR inhibitor
Autophagy,mTOR,PI3K
PIK3CA
MTOR
PI3K
mTORC1
p110α
p110β
p110γ
p110δ
Recommended Cell Concentration
100 nM
Source data
